Effects of Salvianolate Injection on the Pharmacodynamics and Pharmacokinetics of Warfarin in Rats in vivo

IF 16.4 1区 化学 Q1 CHEMISTRY, MULTIDISCIPLINARY Accounts of Chemical Research Pub Date : 2024-03-01 DOI:10.2174/0115734110289980240201073715
Yue Zhao, Jiahui Sun, Shiwei Xu, Yan Liu, Mengnan Qin, Chunjuan Yang, Gaofeng Liu
{"title":"Effects of Salvianolate Injection on the Pharmacodynamics and Pharmacokinetics of Warfarin in Rats in vivo","authors":"Yue Zhao, Jiahui Sun, Shiwei Xu, Yan Liu, Mengnan Qin, Chunjuan Yang, Gaofeng Liu","doi":"10.2174/0115734110289980240201073715","DOIUrl":null,"url":null,"abstract":"Background:: Both Salvianolate Injection and warfarin are widely prescribed in patients with cardiovascular diseases, but the interaction between them is unknown and needs to be investigated. Objective:: This research aims to study the effects and mechanism of Salvianolate Injection on the pharmacodynamics and pharmacokinetics of warfarin in rats. Methods:: Male Wistar rats were intraperitoneally injected Salvianolate Injection (18 mg/kg) with or without oral administration of warfarin (0.2 mg/kg). A coagulation analyzer evaluated prothrombin time (PT) and activated partial thromboplastin time (APTT). International normalized ratio (INR) was calculated based on PT. UPLC-MS/MS combined with a chiral column was used to separate and measure the plasma concentration of R-warfarin and S-warfarin. Agilent SB-C18 column (1.8 μm, 2.1 mm × 50 mm) was used for separation, column temperature at 20°C. The isocratic mobile phase was acetonitrile-aqueous ammonium acetate (5 mM, pH 4) at a flow rate of 0.2 mL/min and 11.5 min for each injection. Pharmacokinetic parameters were calculated using DAS 2.0 software. Results:: Salvianolate Injection increased PT and INR (p < 0.05), while APTT was unaffected (p > 0.05). Compared with the warfarin group, the co-administration of Salvianolate Injection and singledose warfarin enlarged PT and INR (p < 0.05). Similar increases in pharmacokinetic parameters of R-warfarin and S-warfarin, including Cmax, AUC0-t, AUC0-∞, t1/2, and CL/F (p < 0.05), were observed in the co-administration group. A steady-state study of warfarin indicated that PT and INR in the coadministration group are longer than those in the warfarin group (p < 0.05). On days 7th and 8th of warfarin treatment (two and three days after Salvianolate Injection treatment), the plasma concentration of R-warfarin increased by 47.22% and 50.16% (p < 0.05), and plasma concentration of Swarfarin increased by 32.39% and 45.99% (p < 0.05), respectively. Conclusion:: Salvianolate Injection exhibits an anticoagulation effect in rats. Salvianolate Injection can enhance the anticoagulant effect of warfarin by slowing metabolism and increasing the concentration of both enantiomers. These results suggest that the combination of Salvianolate Injection and warfarin should be avoided or closely monitored in case of increasing bleeding risk.","PeriodicalId":1,"journal":{"name":"Accounts of Chemical Research","volume":null,"pages":null},"PeriodicalIF":16.4000,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Accounts of Chemical Research","FirstCategoryId":"92","ListUrlMain":"https://doi.org/10.2174/0115734110289980240201073715","RegionNum":1,"RegionCategory":"化学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CHEMISTRY, MULTIDISCIPLINARY","Score":null,"Total":0}
引用次数: 0

Abstract

Background:: Both Salvianolate Injection and warfarin are widely prescribed in patients with cardiovascular diseases, but the interaction between them is unknown and needs to be investigated. Objective:: This research aims to study the effects and mechanism of Salvianolate Injection on the pharmacodynamics and pharmacokinetics of warfarin in rats. Methods:: Male Wistar rats were intraperitoneally injected Salvianolate Injection (18 mg/kg) with or without oral administration of warfarin (0.2 mg/kg). A coagulation analyzer evaluated prothrombin time (PT) and activated partial thromboplastin time (APTT). International normalized ratio (INR) was calculated based on PT. UPLC-MS/MS combined with a chiral column was used to separate and measure the plasma concentration of R-warfarin and S-warfarin. Agilent SB-C18 column (1.8 μm, 2.1 mm × 50 mm) was used for separation, column temperature at 20°C. The isocratic mobile phase was acetonitrile-aqueous ammonium acetate (5 mM, pH 4) at a flow rate of 0.2 mL/min and 11.5 min for each injection. Pharmacokinetic parameters were calculated using DAS 2.0 software. Results:: Salvianolate Injection increased PT and INR (p < 0.05), while APTT was unaffected (p > 0.05). Compared with the warfarin group, the co-administration of Salvianolate Injection and singledose warfarin enlarged PT and INR (p < 0.05). Similar increases in pharmacokinetic parameters of R-warfarin and S-warfarin, including Cmax, AUC0-t, AUC0-∞, t1/2, and CL/F (p < 0.05), were observed in the co-administration group. A steady-state study of warfarin indicated that PT and INR in the coadministration group are longer than those in the warfarin group (p < 0.05). On days 7th and 8th of warfarin treatment (two and three days after Salvianolate Injection treatment), the plasma concentration of R-warfarin increased by 47.22% and 50.16% (p < 0.05), and plasma concentration of Swarfarin increased by 32.39% and 45.99% (p < 0.05), respectively. Conclusion:: Salvianolate Injection exhibits an anticoagulation effect in rats. Salvianolate Injection can enhance the anticoagulant effect of warfarin by slowing metabolism and increasing the concentration of both enantiomers. These results suggest that the combination of Salvianolate Injection and warfarin should be avoided or closely monitored in case of increasing bleeding risk.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
丹酚酸盐注射液对大鼠体内华法林药效学和药代动力学的影响
背景丹参酮注射液和华法林都是心血管疾病患者的常用药,但二者之间的相互作用尚不清楚,需要进行研究。研究目的本研究旨在探讨丹参酸钠注射液对大鼠华法林药效学和药代动力学的影响和机制。方法雄性 Wistar 大鼠在口服或不口服华法林(0.2 毫克/千克)的情况下腹腔注射丹参酸钠注射液(18 毫克/千克)。凝血分析仪评估凝血酶原时间(PT)和活化部分凝血活酶时间(APTT)。根据 PT 计算出国际正常化比率(INR)。UPLC-MS/MS 与手性色谱柱相结合,用于分离和测量血浆中 R-warfarin 和 S-warfarin 的浓度。采用安捷伦 SB-C18 色谱柱(1.8 μm,2.1 mm × 50 mm)进行分离,柱温为 20°C。等度流动相为乙腈-乙酸铵水溶液(5 mM,pH 4),流速为 0.2 mL/min,每次进样时间为 11.5 min。使用 DAS 2.0 软件计算药代动力学参数。结果丹参酸钠注射液增加了 PT 和 INR(p < 0.05),而 APTT 不受影响(p > 0.05)。与华法林组相比,同时服用丹参乙酸盐注射液和单剂量华法林扩大了 PT 和 INR(p < 0.05)。在联合用药组,观察到 R-warfarin 和 S-warfarin 的药代动力学参数,包括 Cmax、AUC0-t、AUC0-∞、t1/2 和 CL/F 有类似的增加(p <;0.05)。华法林的稳态研究表明,联合用药组的 PT 和 INR 比华法林组更长(p < 0.05)。在华法林治疗的第 7 天和第 8 天(丹参注射液治疗后的第 2 天和第 3 天),R-华法林的血浆浓度分别增加了 47.22% 和 50.16%(p <0.05),Swarfarin 的血浆浓度分别增加了 32.39% 和 45.99%(p <0.05)。结论丹酚注射液对大鼠具有抗凝作用。丹参乙酸盐注射液可通过减缓代谢和增加两种对映体的浓度来增强华法林的抗凝作用。这些结果表明,如果出血风险增加,应避免丹酚酸盐注射液与华法林合用或密切监测。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Accounts of Chemical Research
Accounts of Chemical Research 化学-化学综合
CiteScore
31.40
自引率
1.10%
发文量
312
审稿时长
2 months
期刊介绍: Accounts of Chemical Research presents short, concise and critical articles offering easy-to-read overviews of basic research and applications in all areas of chemistry and biochemistry. These short reviews focus on research from the author’s own laboratory and are designed to teach the reader about a research project. In addition, Accounts of Chemical Research publishes commentaries that give an informed opinion on a current research problem. Special Issues online are devoted to a single topic of unusual activity and significance. Accounts of Chemical Research replaces the traditional article abstract with an article "Conspectus." These entries synopsize the research affording the reader a closer look at the content and significance of an article. Through this provision of a more detailed description of the article contents, the Conspectus enhances the article's discoverability by search engines and the exposure for the research.
期刊最新文献
Management of Cholesteatoma: Hearing Rehabilitation. Congenital Cholesteatoma. Evaluation of Cholesteatoma. Management of Cholesteatoma: Extension Beyond Middle Ear/Mastoid. Recidivism and Recurrence.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1